重大事件
外國發行人報告
6-K
2026-06-29
Haleon披露6月22至26日回購近700萬股普通股用於註銷
AI 繁中摘要
Haleon plc（股票代碼：HLN）於2026年6月29日提交6-K報告，披露其根據3月12日公布的股份回購計劃，在6月22日至26日期間回購了合共6,992,435股普通股（每股面值0.01英鎊），全部用於註銷。📉
回購詳情：
- 6月22日：於倫敦證券交易所、CBOE（BXE/CXE）及Aquis共購入3,992,435股，加權平均價介乎332.11至332.28便士，最高價333.80便士、最低價329.50便士。
- 6月23日：再購入2,999,998股（僅限倫交所及CBOE），加權平均價約334.32至334.44便士，最高價335.00便士、最低價333.10便士。
- 6月24日至26日：無進一步回購。
完成結算後，公司註冊股本為8,820,906,422股，其中12,006,714股為庫存股，即具有投票權的普通股為8,808,899,708股。股東可參考此數字，以判斷是否需要根據FCA的披露指引通知其持股權益變動。
本次回購反映Haleon管理層對資本回報策略的執行，透過減少流通股數，有望提升每股盈利（EPS）及股東價值，對投資者屬正面信號。個別交易的完整明細已於倫敦證券交易所RNS公布，投資者可自行查閱。
展開英文正文
6-K 1 a0397k.htm TRANSACTIONS IN OWN SHARES a0397k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2026 Commission File Number: 001-41411 Haleon plc (Translation of registrant’s name into English) Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐ EXHIBIT INDEX Exhibit Number Description 99.1 29 June 2026 - “Transactions in Own Shares” 99.1 Haleon plc: Aggregated information - transactions in own shares 29 June 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 6,992,435 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026. London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Aquis Date of purchase: 22 June 2026 Number of Shares purchased: 1,834,353 867,176 895,922 394,984 Highest price paid per Share (p): 333.8000 333.8000 333.8000 333.5000 Lowest price paid per Share (p): 329.5000 329.5000 329.5000 329.5000 Volume weighted average price paid per Share (p): 332.1356 332.1429 332.2807 332.1128 Date of purchase: 23 June 2026 Number of Shares purchased: 1,749,546 754,902 495,552 - Highest price paid per Share (p): 335.0000 335.0000 335.0000 - Lowest price paid per Share (p): 333.1000 333.1000 333.1000 - Volume weighted average price paid per Share (p): 334.4367 334.4425 334.3200 - Date of purchase: 24 June 2026 Number of Shares purchased: - - - - Highest price paid per Share (p): - - - - Lowest price paid per Share (p): - - - - Volume weighted average price paid per Share (p): - - - - Date of purchase: 25 June 2026 Number of Shares purchased: - - - - Highest price paid per Share (p): - - - - Lowest price paid per Share (p): - - - - Volume weighted average price paid per Share (p): - - - - Date of purchase: 26 June 2026 Number of Shares purchased: - - - - Highest price paid per Share (p): - - - - Lowest price paid per Share (p): - - - - Volume weighted average price paid per Share (p): - - - - Following the settlement of the above, the Company's registered share capital is 8,820,906,422 ordinary shares of £0.01 each, of which 12,006,714 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,808,899,708 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules. In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below: http://www.rns-pdf.londonstockexchange.com/rns/0378K_1-2026-6-26.pdf This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction. This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors. Enquiries Investors Media Jo Russell +44 7787 392441 Zoë Bird +44 7736 746167 Rakesh Patel +44 7552 484646 Victoria Durman +44 7894 505730 Email: [email protected] Email: [email protected] About Haleon Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world. For more information, please visit www.haleon.com. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HALEON PLC (Registrant) Date: June 29, 2026 By: /s/ Amanda Mellor Name: Amanda Mellor Title: Company Secretary